Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Oppenheimer analyst Hartaj Singh maintains Cellectis (NASDAQ:CLLS) with a Outperform and lowers the price target from $11 to...
UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and evaluated in BALLI-01, a Phase 1/2 open-label dose-esc...
JMP Securities analyst Silvan Tuerkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $6 price ta...
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.33) by ...
As part of the Additional Investment, AstraZeneca subscribed today for 10,000,000 "class A" convertible preferred share...
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platf...
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.26) b...
